Moores Member Champions New Cancer Genetic Risk Assessment Guidelines |
Moores Member Samir Gupta, MD has commented on the significance of the updated National Comprehensive Cancer Network guidelines, which include additional tumor types. These guidelines will enhance personalized cancer care and help healthcare professionals manage genetic risks across a wider range of cancers. Learn More >>
|
Moores Associate Director of Clinical Science Candidate for ASCO Nominating Committee
|
Rana McKay, MD is committed to conquering cancer through excellence in research, leadership, and patient care, making her an excellent choice for this committee. Cast your vote for Dr. McKay before Tuesday, December 3, 2024 at 3:00 p.m. EST. Learn More and Vote >>
|
Mark Your Calendars: 2025 Moores Annual Scientific Retreat
|
Next year’s retreat will be held from 8:00 a.m. to 5:00 p.m. on Thursday November 6, 2025 at the Scripps Seaside Forum. Moores looks forward to this day of collaboration and education.
|
|
|
Moores CRTEC Speed Mentor Workshop
|
Participate this Thursday, November 14, 2024 to gain expert advice from Moores Members Yuan Chen, PhD and Paula Aristizabal, MD, MAS.
|
Sanford SCI-FI Seminars 2024–2025: Speaker Sign Ups
|
The Sanford Consortium and the Sanford Institute Discovery Center invites trainees and research staff to present stem cell-related research at the Sanford Stem Cell Institute Future Innovators (SCI-FI) seminar series.
SCI-FI seminars will be held in-person. Presentations will be 20 minutes, followed by 10 minutes of Q&A. Seminars will take place at the Sanford Consortium conference room 1013A/B from 3:00 p.m. to 4:00 p.m. on the 2nd and 4th Thursday of the month.
Outstanding graduate students, postdocs, and research scientists/staff are encouraged to present. The deadline to sign up is this Friday, November 15, 2024. Invited speakers will be featured on the Sanford website and have the chance to win the "Outstanding Speaker Award" and a $250 gift card.
|
|
|
FEATURED FUNDING OPPORTUNITIES |
Application Deadline: February 14, 2025
LOI Deadline: January 14, 2025
Budget: $275,000 for 2 years
|
Application Deadline: February 14, 2025
LOI Deadline: January 14, 2025
Budget: $500,000/year for 5 years
|
- Breakthrough Award Levels 1 and 2
- Breakthrough Award Level 3
- Breakthrough Award Level 4
- Clinical Research Extension Award
- Era of Hope Scholar Award
-
Transformative Breast Cancer Consortium Award
- Transformative Breast Cancer Consortium Development Award
|
|
|
| Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis
|
Rohit Loomba, MD (Cancer Control)
|
|
|
| Origins and impact of extrachromosomal DNA
|
Vineet Bafna, PhD (Structural and Functional Genomics)
|
|
|
|
Inhibition of RNA splicing triggers CHMP7 nuclear entry, impacting TDP-43 function and leading to the onset of ALS cellular phenotypes
|
Uri Manor, PhD (Cancer Biology and Signaling) and Gene W. Yeo, PhD (Structural and Functional Genomics)
|
|
|
| Cyclin B3 is a dominant fast-acting cyclin that drives rapid early embryonic mitoses
|
Karen F. Oegema, PhD (Cancer Biology and Signaling) and Arshad Desai, PhD (Cancer Biology and Signaling)
|
|
|
CLINICAL TRIALS OFFICE (CTO) |
EG-70-101: A Phase I/II Study of EG70 as an Intravesical Administration to Patients with BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naive or Received Incomplete BCG Treatment
PI: Amirali Salmasi, MD
NCT: NCT04752722
|
|
|
|
